MIRA Pharmaceuticals (MIRA) Competitors $1.23 +0.02 (+1.65%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.41%) As of 05/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. ORMP, ANIX, CLLS, CLYM, PLRX, SNTI, GALT, ADAG, OCX, and GNTAShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Cellectis (CLLS), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), Adagene (ADAG), OncoCyte (OCX), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Oramed Pharmaceuticals Anixa Biosciences Cellectis Climb Bio Pliant Therapeutics Senti Biosciences Galectin Therapeutics Adagene OncoCyte Genenta Science Oramed Pharmaceuticals (NASDAQ:ORMP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Which has preferable earnings & valuation, ORMP or MIRA? Oramed Pharmaceuticals has higher revenue and earnings than MIRA Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M65.54$5.53M-$0.44-4.89MIRA PharmaceuticalsN/AN/A-$11.98M-$0.51-2.41 Is ORMP or MIRA more profitable? Oramed Pharmaceuticals' return on equity of -7.27% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -7.27% -6.20% MIRA Pharmaceuticals N/A -337.44%-280.58% Do institutionals and insiders believe in ORMP or MIRA? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate ORMP or MIRA? MIRA Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,038.21%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media refer more to ORMP or MIRA? In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.53 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ORMP or MIRA? Oramed Pharmaceuticals has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Does the MarketBeat Community prefer ORMP or MIRA? Oramed Pharmaceuticals received 316 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 71.85% of users gave Oramed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOramed PharmaceuticalsOutperform Votes31971.85% Underperform Votes12528.15% MIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo Votes SummaryOramed Pharmaceuticals beats MIRA Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.81M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-2.209.0626.7119.71Price / SalesN/A251.51386.08120.53Price / CashN/A65.8538.2534.62Price / Book4.106.456.774.50Net Income-$11.98M$143.98M$3.23B$248.22M7 Day Performance-15.17%0.38%0.48%-0.78%1 Month Performance33.55%2.14%9.10%11.53%1 Year Performance39.77%-0.33%18.56%8.99% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals1.3984 of 5 stars$1.23+1.7%$14.00+1,038.2%+34.3%$20.81MN/A-2.202ORMPOramed Pharmaceuticals1.8017 of 5 stars$2.14-0.5%N/A-6.5%$87.42M$1.34M19.4510ANIXAnixa Biosciences1.7202 of 5 stars$2.70+1.9%$9.00+233.3%+0.0%$86.93M$210,000.00-6.925CLLSCellectis2.7847 of 5 stars$1.55-1.9%$6.67+330.1%-46.2%$86.16M$47.63M-1.19290News CoverageAnalyst DowngradeCLYMClimb Bio2.7008 of 5 stars$1.27-1.6%$10.00+687.4%N/A$85.82MN/A-0.609News CoverageAnalyst ForecastAnalyst RevisionPLRXPliant Therapeutics4.2506 of 5 stars$1.35-2.2%$13.31+886.1%-90.6%$84.71M$1.58M-0.4090News CoveragePositive NewsSNTISenti Biosciences1.6937 of 5 stars$3.24+1.9%$12.00+270.4%-16.3%$84.50M$2.56M-0.214GALTGalectin Therapeutics1.2113 of 5 stars$1.33+3.9%$11.00+727.1%-58.8%$84.03MN/A-1.829Earnings ReportADAGAdagene1.7913 of 5 stars$1.77flat$8.00+352.0%-37.7%$83.39M$103,204.000.00260News CoverageOCXOncoCyte2.6017 of 5 stars$2.80+0.4%$4.42+57.7%+18.2%$80.08M$3.84M-0.79120Analyst ForecastGNTAGenenta Science1.4863 of 5 stars$4.37+2.9%$25.00+471.6%+34.4%$80MN/A0.007Gap Up Related Companies and Tools Related Companies Oramed Pharmaceuticals Competitors Anixa Biosciences Competitors Cellectis Competitors Climb Bio Competitors Pliant Therapeutics Competitors Senti Biosciences Competitors Galectin Therapeutics Competitors Adagene Competitors OncoCyte Competitors Genenta Science Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.